(FATE) Fate Therapeutics - Ratings and Ratios
iPSC-Derived, CAR-NK, CAR-T, Stem Cell, Cancer Therapy
FATE EPS (Earnings per Share)
FATE Revenue
Description: FATE Fate Therapeutics
Fate Therapeutics Inc (NASDAQ:FATE) is a biotechnology company based in the United States, focusing on developing innovative therapies. The companys stock is characterized by high volatility, as indicated by its beta of 2.245, suggesting that its stock price movements are more than twice as sensitive as the overall market.
The stocks recent price action shows a relatively stable trading range, with the last price at $1.14, slightly above its 20-day Simple Moving Average (SMA) of $1.11, but below its 50-day SMA of $1.16 and significantly below its 200-day SMA of $1.41. This indicates a potential downtrend in the stocks longer-term performance. The Average True Range (ATR) of 0.08 represents a 6.76% daily price movement, highlighting the stocks volatility.
From a fundamental perspective, Fate Therapeutics has a market capitalization of $125.71 million, with a negative Return on Equity (RoE) of -55.74%, indicating that the company is currently unprofitable. The absence of a Price-to-Earnings (P/E) ratio, either trailing or forward, further emphasizes the companys lack of profitability. Key economic drivers for the company include its pipeline progress, partnerships, and the overall demand for its therapeutic areas of focus.
To assess the companys potential, key performance indicators (KPIs) such as cash burn rate, research and development (R&D) expenses as a percentage of revenue, and the advancement of its clinical trials are crucial. Investors should also monitor the companys ability to secure additional funding, either through equity financing, partnerships, or grants, to support its operations and R&D activities. The biotechnology sectors overall trends, including regulatory changes and competitor activity, will also impact Fate Therapeutics stock performance.
FATE Stock Overview
| Market Cap in USD | 111m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2013-10-01 |
FATE Stock Ratings
| Growth Rating | -90.7% |
| Fundamental | 28.3% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -79.7% |
| Analyst Rating | 3.67 of 5 |
FATE Dividends
Currently no dividends paidFATE Growth Ratios
| Growth Correlation 3m | -61.4% |
| Growth Correlation 12m | -76.4% |
| Growth Correlation 5y | -94.4% |
| CAGR 5y | -66.79% |
| CAGR/Max DD 3y | -0.69 |
| CAGR/Mean DD 3y | -0.78 |
| Sharpe Ratio 12m | -2.21 |
| Alpha | -93.52 |
| Beta | 0.846 |
| Volatility | 80.77% |
| Current Volume | 1087k |
| Average Volume 20d | 1339.9k |
| Stop Loss | 0.8 (-16.7%) |
| Signal | -0.81 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-171.5m TTM) > 0 and > 6% of Revenue (6% = 508.2k TTM) |
| FCFTA -0.33 (>2.0%) and ΔFCFTA -7.09pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 2382 % (prev 2311 %; Δ 71.04pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.31 (>3.0%) and CFO -115.6m > Net Income -171.5m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 8.04 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (118.5m) change vs 12m ago 0.90% (target <= -2.0% for YES) |
| Gross Margin -49.92% (prev -55.61%; Δ 5.70pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 1.88% (prev 2.33%; Δ -0.45pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' -26.02
| (A) 0.54 = (Total Current Assets 230.4m - Total Current Liabilities 28.7m) / Total Assets 371.6m |
| (B) -3.95 = Retained Earnings (Balance) -1.47b / Total Assets 371.6m |
| warn (B) unusual magnitude: -3.95 — check mapping/units |
| (C) -0.40 = EBIT TTM -180.9m / Avg Total Assets 450.2m |
| (D) -13.33 = Book Value of Equity -1.47b / Total Liabilities 110.3m |
| Total Rating: -26.02 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 28.25
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield data missing |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.33 = 2.45 |
| 5. Debt/Ebitda -0.53 = -2.50 |
| 6. ROIC - WACC -67.78% = -12.50 |
| 7. RoE -55.74% = -2.50 |
| 8. Rev. Trend -60.96% = -4.57 |
| 9. EPS Trend 57.44% = 2.87 |
What is the price of FATE shares?
Over the past week, the price has changed by -1.06%, over one month by -12.31%, over three months by -22.92% and over the past year by -75.86%.
Is Fate Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of FATE is around 0.33 USD . This means that FATE is currently overvalued and has a potential downside of -65.63%.
Is FATE a buy, sell or hold?
- Strong Buy: 3
- Buy: 2
- Hold: 7
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the FATE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 4.5 | 363.5% |
| Analysts Target Price | 4.5 | 363.5% |
| ValueRay Target Price | 0.4 | -61.5% |
Last update: 2025-09-10 04:37
FATE Fundamental Data Overview
CCE Cash And Equivalents = 222.8m USD (Cash And Short Term Investments, last quarter)
P/S = 13.1533
P/B = 0.4457
Beta = 2.216
Revenue TTM = 8.47m USD
EBIT TTM = -180.9m USD
EBITDA TTM = -164.9m USD
Long Term Debt = 81.6m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 5.66m USD (from shortTermDebt, last quarter)
Debt = 87.3m USD (Calculated: Short Term 5.66m + Long Term 81.6m)
Net Debt = 40.1m USD (from netDebt column, last quarter)
Enterprise Value = -24.2m USD (111.4m + Debt 87.3m - CCE 222.8m)
Interest Coverage Ratio = unknown (Ebit TTM -180.9m / Interest Expense TTM 0.0)
FCF Yield = -511.4% (FCF TTM -123.6m / Enterprise Value -24.2m)
FCF Margin = -1459 % (FCF TTM -123.6m / Revenue TTM 8.47m)
Net Margin = -2025 % (Net Income TTM -171.5m / Revenue TTM 8.47m)
Gross Margin = -49.92% ((Revenue TTM 8.47m - Cost of Revenue TTM 12.7m) / Revenue TTM)
Tobins Q-Ratio = 0.02 (Enterprise Value -24.2m / Book Value Of Equity -1.47b)
Interest Expense / Debt = 11.13% (Interest Expense 9.71m / Debt 87.3m)
Taxrate = 21.0% (US default)
NOPAT = -180.9m (EBIT -180.9m, no tax applied on loss)
Current Ratio = 8.04 (Total Current Assets 230.4m / Total Current Liabilities 28.7m)
Debt / Equity = 0.33 (Debt 87.3m / last Quarter total Stockholder Equity 261.4m)
Debt / EBITDA = -0.53 (Net Debt 40.1m / EBITDA -164.9m)
Debt / FCF = -0.71 (Debt 87.3m / FCF TTM -123.6m)
Total Stockholder Equity = 307.7m (last 4 quarters mean)
RoA = -46.15% (Net Income -171.5m, Total Assets 371.6m )
RoE = -55.74% (Net Income TTM -171.5m / Total Stockholder Equity 307.7m)
RoCE = -46.47% (Ebit -180.9m / (Equity 307.7m + L.T.Debt 81.6m))
RoIC = -58.79% (NOPAT -180.9m / Invested Capital 307.7m)
WACC = 8.98% (E(111.4m)/V(198.7m) * Re(9.13%)) + (D(87.3m)/V(198.7m) * Rd(11.13%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 100.00 | Cagr: 1.84%
Discount Rate = 9.13% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -123.6m)
EPS Correlation: 57.44 | EPS CAGR: 0.0% | SUE: 0.93 | # QB: True
Revenue Correlation: -60.96 | Revenue CAGR: -52.74%
Additional Sources for FATE Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle